AxoGen (AXGN) Investor Presentation - Slideshow

Financial Performance & Market Position - Q3 2020 revenue reached $33.4 million, a 17% increase compared to Q3 2019[8] - 2019 revenue totaled $106.7 million, demonstrating 27% growth versus 2018[8] - High gross margins were sustained at 83.0% for the quarter ended September 30, 2020[8] - Cash, cash equivalents, and investments amounted to $106.7 million as of September 30, 2020[8] - The company estimates a $2.7 billion market opportunity in existing applications[15] Market Opportunity & Procedures - The U S potential procedural estimates exceed 900,000[14] - Trauma procedures account for over 700,000 of the potential procedures[14] - Carpal Tunnel Revisions & Cubital Tunnel procedures account for 130,000 of the potential procedures[14] - Oral and Maxillo-Facial (OMF) procedures account for over 55,000 of the potential procedures[14]